Dehydrocostus lactone attenuates atherogenesis by promoting cholesterol efflux and inhibiting inflammation via TLR2/PPAR-γ/NF-κB signaling pathway

Mol Med. 2025 Jun 19;31(1):243. doi: 10.1186/s10020-025-01265-8.

Abstract

BACKGROUND: Dehydrocostus lactone (DHL), a natural sesquiterpene lactone, has significant anti-inflammatory effects and has the potential to inhibit ox-LDL-induced atherosclerosis in laboratory settings. However, the in vivo anti-atherosclerotic effects of DHL and their molecular mechanisms remain unclear. This study explores the anti-atherosclerosis effects of DHL on apolipoprotein E-deficient (ApoE−/−) mice, and the potential mechanism on macrophage-derived foam cells. METHODS: Blood lipid and arterial plaque were assessed to evaluate the anti-atherosclerosis effect. The levels of inflammatory cytokines were quantified by ELISA assay. A serum metabolomics assay was performed to determine the changes in blood metabolites. A cholesterol efflux assay was used to measure the cholesterol efflux rate. Expression of genes or proteins were examined by qRT-PCR, western blot analysis, or immunofluorescence staining. RESULTS: Treatment with DHL greatly reduced blood lipid levels and decreased the formation of atherosclerotic plaques in the aorta in high-fat diet-fed ApoE−/− mice. DHL treatment enhanced cholesterol efflux from foam cells by increasing the expression of ATP-binding cassette (ABC) A1, ABCG1, and peroxisome proliferator-activated receptor gamma (PPAR-γ), both in vitro and in vivo. DHL treatment decreased the levels of IL-1β and TNF-α, elevated IL-10 levels, and promoted the formation of M2 macrophages by inhibiting myeloid differentiation factor 88 and nuclear factor kappa B (NF-κB). Inhibition of TLR2 in foam cells derived from macrophages significantly reduced the inflammatory response and enhanced cholesterol efflux. CONCLUSION: This study demonstrates that treatment with DHL alleviates atherosclerosis by promoting cholesterol efflux and inhibiting inflammation through the TLR2/PPAR-γ/NF-κB signaling pathway.

Keywords: Anti-inflammation; Atherosclerosis; Cholesterol efflux; Dehydrocostus lactone; Toll-like receptor 2.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents* / pharmacology
  • Apolipoproteins E / genetics
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / etiology
  • Atherosclerosis* / metabolism
  • Atherosclerosis* / pathology
  • Cholesterol* / metabolism
  • Cytokines / metabolism
  • Disease Models, Animal
  • Foam Cells / drug effects
  • Foam Cells / metabolism
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Lactones* / pharmacology
  • Lactones* / therapeutic use
  • Male
  • Mice
  • NF-kappa B* / metabolism
  • PPAR gamma* / metabolism
  • Sesquiterpenes* / pharmacology
  • Sesquiterpenes* / therapeutic use
  • Signal Transduction* / drug effects
  • Toll-Like Receptor 2* / metabolism

Substances

  • Toll-Like Receptor 2
  • NF-kappa B
  • Cholesterol
  • Sesquiterpenes
  • PPAR gamma
  • Lactones
  • dehydrocostus lactone
  • Tlr2 protein, mouse
  • Anti-Inflammatory Agents
  • Apolipoproteins E
  • Cytokines